Literature DB >> 24694725

Polish guidelines for the diagnosis and management of osteoporosis: a review of 2013 update.

Piotr Głuszko, Roman S Lorenc, Elżbieta Karczmarewicz, Waldemar Misiorowski, Maciej Jaworski.   

Abstract

To decrease the risk of osteoporotic fractures in Poland, the Multidisciplinary Osteoporotic Forum has set up a joint Working Group including the representatives of the Polish Associations of Orthopedics and Traumatology, Rehabilitation, Gerontology, Rheumatology, Family Medicine, Diabetology, Laboratory Diagnostics, Andropause and Menopause, Endocrinology, Radiology, and the STENKO group as well as experts in the fields of rheumatology, obstetrics, and geriatrics to update the Polish guidelines for the diagnosis and management of osteoporosis in men and postmenopausal women in Poland. The assessment of fracture risk and intervention thresholds was made using the FRAX® calculation tool for Poland. The strength of recommendations was evaluated according to the principles of the Scottish Intercollegiate Guidelines Network and the results have been approved by national consultants. Finally, the Working Group has formulated the updated guidelines and recommended two -step diagnostic and therapeutic procedures. The first stage applies to family physicians or general practitioners and involves the assessment of fracture risk using the FRAX®-BMI to identify patients at high risk of fractures. An osteoporotic fracture remains an absolute indication both for the general practitioner and specialist to implement treatment. At the second stage, the specialist (in an osteoporosis or other specialty clinic) should review the primary or secondary causes of fracture risk, confirm the diagnosis, and introduce an appropriate treatment and monitoring. In patients (men aged >50 years and postmenopausal women) without low-energy fractures, the absolute risk of fractures exceeding 10% should be considered an indication for treatment. The Polish guidelines were compared with other international guidelines in terms of diagnostic measures, pharmacotherapy, as well as calcium and vitamin D supplementation.

Entities:  

Mesh:

Year:  2014        PMID: 24694725     DOI: 10.20452/pamw.2255

Source DB:  PubMed          Journal:  Pol Arch Med Wewn


  9 in total

1.  Fragility of results from randomized controlled trials supporting the guidelines for the treatment of osteoporosis: a retrospective analysis.

Authors:  X Huang; B Chen; L Thabane; J D Adachi; G Li
Journal:  Osteoporos Int       Date:  2021-02-17       Impact factor: 4.507

Review 2.  A systematic review of intervention thresholds based on FRAX : A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation.

Authors:  John A Kanis; Nicholas C Harvey; Cyrus Cooper; Helena Johansson; Anders Odén; Eugene V McCloskey
Journal:  Arch Osteoporos       Date:  2016-07-27       Impact factor: 2.617

3.  The FRAX-based Lebanese osteoporosis treatment guidelines: rationale for a hybrid model.

Authors:  M Chakhtoura; W D Leslie; M McClung; A M Cheung; G El-Hajj Fuleihan
Journal:  Osteoporos Int       Date:  2016-09-20       Impact factor: 4.507

Review 4.  Osteoporosis in liver disease: pathogenesis and management.

Authors:  Gabriela Handzlik-Orlik; Michał Holecki; Krzysztof Wilczyński; Jan Duława
Journal:  Ther Adv Endocrinol Metab       Date:  2016-04-06       Impact factor: 3.565

Review 5.  Treatment recommendations based on fracture risk status are not consistently provided in osteoporosis guidelines.

Authors:  Joanna E M Sale; Matthew Gray; Daniel Mancuso; Taucha Inrig; Gilles Boire; Marie-Claude Beaulieu; Larry Funnell; Earl Bogoch
Journal:  Rheumatol Int       Date:  2018-10-26       Impact factor: 2.631

6.  Assessing the clinical utility of genetic profiling in fracture risk prediction: a decision curve analysis.

Authors:  T P Ho-Le; H T T Tran; J R Center; J A Eisman; H T Nguyen; T V Nguyen
Journal:  Osteoporos Int       Date:  2020-08-12       Impact factor: 4.507

7.  Evaluation of the validity of treatment decisions based on surrogate country models before introduction of the Polish FRAX and recommendations in comparison to current practice.

Authors:  Wojciech M Glinkowski; Jerzy Narloch; Bożena Glinkowska; Małgorzata Bandura
Journal:  Arch Med Sci       Date:  2016-06-23       Impact factor: 3.318

8.  Screening to prevent fragility fractures among adults 40 years and older in primary care: protocol for a systematic review.

Authors:  Michelle Gates; Jennifer Pillay; Guylène Thériault; Heather Limburg; Roland Grad; Scott Klarenbach; Christina Korownyk; Donna Reynolds; John J Riva; Brett D Thombs; Gregory A Kline; William D Leslie; Susan Courage; Ben Vandermeer; Robin Featherstone; Lisa Hartling
Journal:  Syst Rev       Date:  2019-08-23

9.  Bisphosphonate use after clinical fracture and risk of new fracture.

Authors:  J Bergman; A Nordström; P Nordström
Journal:  Osteoporos Int       Date:  2018-02-03       Impact factor: 4.507

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.